Ansell launches VivaGel condom in Canada
Filed with ASX · · 3 pages · English
Starpharma Holdings Limited on 6ix
Story so far
Earlier from Starpharma
- VivaGel BV phase 3 trials for prevention of BV completed
- Shareholder Update January 2017
- VivaGel BV granted QIDP and Fast Track designation by US FDA
- Starpharma receives $3.5M R&D tax incentive refund
- Starpharma signs license for VivaGel Condom in Iran
Later from Starpharma
- AstraZeneca DEP candidate advance triggers milestone to SPL
- DEP irinotecan outperforms irinotecan in cancer models
- Starpharma sells Agrochemicals business to Agrium for $35M
- VivaGel BV phase 3 results timing and commercialisation
- Successful VivaGel Phase 3 results and NDA planned for rBV
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma